<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462928</url>
  </required_header>
  <id_info>
    <org_study_id>150998-005</org_study_id>
    <secondary_id>2014-004579-22</secondary_id>
    <secondary_id>CEDAR</secondary_id>
    <nct_id>NCT02462928</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration</brief_title>
  <acronym>CEDAR</acronym>
  <official_title>Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of abicipar pegol in participants with neovascular
      age-related macular degeneration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2015</start_date>
  <completion_date type="Actual">June 19, 2019</completion_date>
  <primary_completion_date type="Actual">April 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Stable Vision at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Stable vision was defined as a loss of fewer than 15 letters in BCVA compared to baseline. BCVA was measured using an eye chart and reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in BCVA in the Study Eye at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>BCVA was measured using an eye chart and was reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their nondominant eye for treatment, or else the right eye was selected as the study eye. Mixed model for repeated measures (MMRM) analysis was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye. MMRM analysis was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Gain of 15 or More ETDRS Letters in BCVA From Baseline in Study Eye at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>BCVA was measured using an eye chart and reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score in Study Eye at Week 52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision related function. The overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding the general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye was defined as eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (day 1) was selected. If BCVA values for both eyes were identical then participant had to select non-dominant eye, or else right eye was selected as study eye. A positive change from baseline indicates improvement. MMRM analysis was used.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">939</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Abicipar Pegol 2 mg (2Q8)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abicipar Pegol 2 mg (2Q12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5 mg (rQ4)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abicipar Pegol</intervention_name>
    <description>Abicipar pegol intravitreal injection.</description>
    <arm_group_label>Abicipar Pegol 2 mg (2Q12)</arm_group_label>
    <arm_group_label>Abicipar Pegol 2 mg (2Q8)</arm_group_label>
    <other_name>AGN-150998</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Ranibizumab intravitreal injection.</description>
    <arm_group_label>Ranibizumab 0.5 mg (rQ4)</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham Procedure</intervention_name>
    <description>Sham injection.</description>
    <arm_group_label>Abicipar Pegol 2 mg (2Q12)</arm_group_label>
    <arm_group_label>Abicipar Pegol 2 mg (2Q8)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of age-related macular degeneration in at least 1 eye

          -  Best corrected visual acuity of 20/40 to 20/320 in the study eye

          -  Best corrected visual acuity of 20/200 or better in the non-study eye

        Exclusion Criteria:

          -  History of vitrectomy, macular surgery, or glaucoma surgery in the study eye

          -  Cataract or refractive surgery in the study eye within the last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Li</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Research Institute, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Retina Consultants, Ltd.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Retina and Vitreous Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates Southwest, P.C.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Partners</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark B. Kislinger MD Inc.</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantis Retina Institute (Atlantis Eyecare)</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates Medical Group, INC.</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of California</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doheny Vision Research</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orange County Retina Medical Group</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Eye Specialists</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Health Center</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Retina Consultants</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ocala Eye PA</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magruder Eye Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Care Specialists</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialty Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida - Saint Petersburg</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USF Eye Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Retina, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Eye Clinic - Main Office</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Eye Group, PC</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Hawaii, Inc.</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gailey Eye Clinic</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle at the Fields</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Retina and Macula Associates, PC</name>
      <address>
        <city>Lemont</city>
        <state>Illinois</state>
        <zip>60439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raj K. Maturi, MD, PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Kenyon American Eye Institute</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Health Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialists</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Bert M Glaser National Retina Institute</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Medical Center</name>
      <address>
        <city>Peabody</city>
        <state>Massachusetts</state>
        <zip>01960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kellog Eye Center - University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of New Jersey</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Region Retina, PLLC</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Vitreoretinal Consultants</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Oceanside</city>
        <state>New York</state>
        <zip>11572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Western New York</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Retina</name>
      <address>
        <city>Shirley</city>
        <state>New York</state>
        <zip>11967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Eye Associates</name>
      <address>
        <city>Southern Pines</city>
        <state>North Carolina</state>
        <zip>28387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health Eye Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apex Eye Clinical Research</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster Retina Specialists</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Ophthalmology, Ltd.</name>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Carolina</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charleston Neuroscience Institute</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texan Eye</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TX Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Eye Associates (HEA) - Gramercy Location</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina and Vitreous of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Eye Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia - Department of Ophthalmology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Eye Center, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Privada Kaufer Cataract Center</name>
      <address>
        <city>Martinez</city>
        <state>Buenos Aires</state>
        <zip>B1640BNT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Austral</name>
      <address>
        <city>Pilar</city>
        <state>Buenos Aires</state>
        <zip>B1629ODT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oftalmologico Rosario SRL</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000ANJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grupo Laser Vision</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000AZH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmologico de Buenos Aires - Oftalmos</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1120AAN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Privado de Ojos Romagosa</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000AAJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmologico de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000IIT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oftar Centro Privado de Oftalmologia</name>
      <address>
        <city>Mendoza</city>
        <zip>M5500GGK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck, Univ.</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kepler Universitatsklinikum GmBH</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Konventhospital Barmherzige Brueder Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KYDOFT</name>
      <address>
        <city>Santiago</city>
        <state>Las Condes</state>
        <zip>7560994</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmologica Profesor Arentsen</name>
      <address>
        <city>Santiago</city>
        <state>Región Metropolitana</state>
        <zip>7510168</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Oftalmologica Nacional - FUNDONAL</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady Oftalmologicka klinika</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze Ocni Klinika</name>
      <address>
        <city>Praha</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Creteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Croix Rousse, Service d'Opthalmologie</name>
      <address>
        <city>Lyon cedex 04</city>
        <zip>69417</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Ophtalmologique d'Imagerie et de Laser</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Ophtalmologique Saint Exupery</name>
      <address>
        <city>Saint Cyr sur Loire</city>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dardenne Eye Hospital</name>
      <address>
        <city>Bad Godesberg</city>
        <zip>53177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dresden Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internationale Innovative Ophthalmochirurgie Breyer &amp; Kaymak &amp; Klabe Augenchirurgie</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Center, University of Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitats-augenklinik Gottingen</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR Klinik und Poliklinik für Augenheilkunde</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Giessen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augenklinik im Dietrich-Bonhoeffer - Klinikum Neubrandenburg</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17036</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic and policlinic of ophthalmology, University of Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Aberdeen</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong Hongkong eye hospital</name>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center (BZMC) Technion-Israel Institute of Technology</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center Ophthalmology Clinic</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center Beilinson Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASMC (The Tel-Aviv Sourasky Medical Centre)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center Goldschleger Eye Clinic Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shamir Medical Centre</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. Of Seoul St. Mary's Hospital</name>
      <address>
        <city>Seocho</city>
        <state>Seoul</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System Serverance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital Opthalmology Clinic</name>
      <address>
        <city>Riga</city>
        <state>LV</state>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Eye</name>
      <address>
        <city>Remuera</city>
        <state>Auckland</state>
        <zip>1051</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Auckland</name>
      <address>
        <city>Auckland</city>
        <zip>1123</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cebu Doctors University Hospital</name>
      <address>
        <city>Cebu City</city>
        <state>Metro Manila</state>
        <zip>6000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Eye Institute</name>
      <address>
        <city>Makati City</city>
        <state>Metro Manila</state>
        <zip>1200</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Eyecare and Laser Institute</name>
      <address>
        <city>Makati City</city>
        <state>Metro Manila</state>
        <zip>1209</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig City</city>
        <state>Metro Manila</state>
        <zip>1600</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <state>Metro Manila</state>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore National Eye Centre- Singapore Eye Research Institute (SNECSERI)</name>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmologia Barraquer</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Clinic d'Oftalmologia Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Microcirugía Ocular DOS, S.L.U Area de Consultas</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valles Oftalmologia Research Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08915</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clínico Quirúrgico de Oftalmología (ICQO)</name>
      <address>
        <city>Bilbao</city>
        <zip>48006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra Servicio de Oftalmologia</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia Unidad de Investigacion Clinica</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa. Unidad de Retina Médica y Quirúrgica</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik fur Augenheilkunde, Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VISTA Klinik Binningen</name>
      <address>
        <city>Binningen</city>
        <zip>4102</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftung für wissenschaftliche Forschung am Stadtspital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Portugal</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>July 16, 2020</results_first_submitted>
  <results_first_submitted_qc>July 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2020</results_first_posted>
  <disposition_first_submitted>March 25, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 29, 2019</disposition_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02462928/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02462928/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Abicipar Pegol 2 mg (2Q8)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="P2">
          <title>Abicipar Pegol 2 mg (2Q12)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="P3">
          <title>Ranibizumab 0.5 mg (rQ4)</title>
          <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="313"/>
                <participants group_id="P3" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="221"/>
                <participants group_id="P3" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="92"/>
                <participants group_id="P3" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure:Missed Exclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Patient</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Abicipar Pegol 2 mg (2Q8)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="B2">
          <title>Abicipar Pegol 2 mg (2Q12)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="B3">
          <title>Ranibizumab 0.5 mg (rQ4)</title>
          <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="314"/>
            <count group_id="B2" value="313"/>
            <count group_id="B3" value="312"/>
            <count group_id="B4" value="939"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="314"/>
                    <count group_id="B2" value="313"/>
                    <count group_id="B3" value="312"/>
                    <count group_id="B4" value="939"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.5" spread="8.4"/>
                    <measurement group_id="B2" value="76.9" spread="8.0"/>
                    <measurement group_id="B3" value="77.1" spread="8.4"/>
                    <measurement group_id="B4" value="76.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="314"/>
                    <count group_id="B2" value="313"/>
                    <count group_id="B3" value="312"/>
                    <count group_id="B4" value="939"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="514"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="152"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="314"/>
                    <count group_id="B2" value="313"/>
                    <count group_id="B3" value="312"/>
                    <count group_id="B4" value="939"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                    <measurement group_id="B2" value="248"/>
                    <measurement group_id="B3" value="243"/>
                    <measurement group_id="B4" value="740"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best-corrected Visual Acuity (BCVA) Per Per-protocol Population</title>
          <description>BCVA was measured using eye chart and reported as number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in study eye. Lower number of letters read correctly on eye chart, worse the vision (or visual acuity). Study eye is defined as eye that meets entry criteria. If both eyes met entry criteria, eye with worse BCVA at baseline (Day 1) was selected as study eye. If both eyes had same BCVA values at baseline (Day 1), then participant had to select their non-dominant eye for treatment, or else right eye was selected as study eye.</description>
          <population>The per-protocol (PP) population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="265"/>
                    <count group_id="B2" value="262"/>
                    <count group_id="B3" value="290"/>
                    <count group_id="B4" value="817"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.7" spread="13.3"/>
                    <measurement group_id="B2" value="56.3" spread="13.1"/>
                    <measurement group_id="B3" value="56.5" spread="12.6"/>
                    <measurement group_id="B4" value="56.5" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BCVA Per ITT Population</title>
          <description>BCVA was measured using eye chart and reported as number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in study eye. Lower number of letters read correctly on eye chart, worse the vision (or visual acuity). Study eye is defined as eye that meets entry criteria. If both eyes met entry criteria, eye with worse BCVA at baseline (Day 1) was selected as study eye. If both eyes had same BCVA values at baseline (Day 1), then participant had to select their non-dominant eye for treatment, or else right eye was selected as study eye.</description>
          <population>Number analyzed is the number of participants with data available at Baseline.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="313"/>
                    <count group_id="B2" value="313"/>
                    <count group_id="B3" value="312"/>
                    <count group_id="B4" value="938"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="13.4"/>
                    <measurement group_id="B2" value="56.5" spread="12.9"/>
                    <measurement group_id="B3" value="56.5" spread="12.5"/>
                    <measurement group_id="B4" value="56.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Central Retinal Thickness (CRT)</title>
          <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.</description>
          <population>Number analyzed is the number of participants with data available at Baseline.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="313"/>
                    <count group_id="B2" value="313"/>
                    <count group_id="B3" value="312"/>
                    <count group_id="B4" value="938"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="384.7" spread="142.7"/>
                    <measurement group_id="B2" value="378.4" spread="119.1"/>
                    <measurement group_id="B3" value="378.2" spread="120.5"/>
                    <measurement group_id="B4" value="380.4" spread="127.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25)</title>
          <description>NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision related function. The overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding the general health score. Overall composite score was calculated based on mean of non-missing subscales.</description>
          <population>Number analyzed is the number of participants with data available at Baseline.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="313"/>
                    <count group_id="B2" value="313"/>
                    <count group_id="B3" value="311"/>
                    <count group_id="B4" value="937"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.7" lower_limit="28" upper_limit="98"/>
                    <measurement group_id="B2" value="77.3" lower_limit="34" upper_limit="98"/>
                    <measurement group_id="B3" value="77.1" lower_limit="23" upper_limit="100"/>
                    <measurement group_id="B4" value="77.7" lower_limit="23" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Stable Vision at Week 52</title>
        <description>Stable vision was defined as a loss of fewer than 15 letters in BCVA compared to baseline. BCVA was measured using an eye chart and reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The per-protocol (PP) population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg (rQ4)</title>
            <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Stable Vision at Week 52</title>
          <description>Stable vision was defined as a loss of fewer than 15 letters in BCVA compared to baseline. BCVA was measured using an eye chart and reported as the number of letters read correctly using the Early Treatment of Diabetic Retinopathy Study (ETDRS) Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The percentage of participants with a BCVA loss of fewer than 15 letters are reported. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.</description>
          <population>The per-protocol (PP) population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="290"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7"/>
                    <measurement group_id="O2" value="91.2"/>
                    <measurement group_id="O3" value="95.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For hypothesis testing, if the lower limit of 95.1% Confidence Interval (CI) for the difference between an abicipar group and ranibizumab was greater than or equal to -10%, non-inferiority of abicipar was established.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-3.8</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>0.3</ci_upper_limit>
            <estimate_desc>The 95.1% CI for the weighted difference were calculated based on the Newcombe method using the Cochran-Mantel-Haenszel weights and baseline BCVA (≤55 vs &gt;55 letters) as stratification factor.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For hypothesis testing, if the lower limit of 95.1% Confidence Interval (CI) for the difference between an abicipar group and ranibizumab was greater than or equal to -10%, non-inferiority of abicipar was established.</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
            <estimate_desc>The 95.1% CI for the weighted difference were calculated based on the Newcombe method using the Cochran-Mantel-Haenszel weights and baseline BCVA (≤55 vs &gt;55 letters) as stratification factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in BCVA in the Study Eye at Week 52</title>
        <description>BCVA was measured using an eye chart and was reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their nondominant eye for treatment, or else the right eye was selected as the study eye. Mixed model for repeated measures (MMRM) analysis was used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The PP population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg (rQ4)</title>
            <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in BCVA in the Study Eye at Week 52</title>
          <description>BCVA was measured using an eye chart and was reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their nondominant eye for treatment, or else the right eye was selected as the study eye. Mixed model for repeated measures (MMRM) analysis was used.</description>
          <population>The PP population included all randomized and treated participants without any protocol deviations that impacted the primary efficacy variable and with treatment compliance to represent the intended regimen adequately. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="241"/>
                <count group_id="O2" value="239"/>
                <count group_id="O3" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="12.9"/>
                    <measurement group_id="O2" value="5.6" spread="13.3"/>
                    <measurement group_id="O3" value="8.5" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For hypothesis testing, non-inferiority of abicipar is established if the lower limit of the CI is &gt; - 5.0 letters.</non_inferiority_desc>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>-2.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
            <estimate_desc>MMRM included treatment, region, BL BCVA, BL CRT ≤400 or &gt;400, choroidal neovascularization lesion type, visit, visit-by-BL BCVA interaction, and treatment-by-visit interaction term as covariates using an unstructured covariance matrix.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>For hypothesis testing, non-inferiority of abicipar is established if the lower limit of the CI is &gt; - 5.0 letters.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-3.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>-1.3</ci_upper_limit>
            <estimate_desc>MMRM included treatment, region, BL BCVA, BL CRT ≤400 or &gt;400, choroidal neovascularization lesion type, visit, visit-by-BL BCVA interaction, and treatment-by-visit interaction term as covariates using an unstructured covariance matrix.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52</title>
        <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye. MMRM analysis was used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>ITT population included all randomized participants. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg (rQ4)</title>
            <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye at Week 52</title>
          <description>CRT was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from Baseline indicated improvement. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye. MMRM analysis was used.</description>
          <population>ITT population included all randomized participants. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
          <units>microns</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="235"/>
                <count group_id="O3" value="269"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-141.5" spread="136.4"/>
                    <measurement group_id="O2" value="-150.1" spread="127.4"/>
                    <measurement group_id="O3" value="-141.3" spread="122.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of abicipar was demonstrated if the lower limit of CI for the treatment difference was greater than zero.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>8.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.3</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.8</ci_lower_limit>
            <ci_upper_limit>20.9</ci_upper_limit>
            <estimate_desc>MMRM was used for analyses with covariates (treatment, region, baseline BCVA, CRT, choroidal neovascularization lesion type, visit, visit by baseline BCVA and treatment by visit interaction) with unstructured covariance matrix.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of abicipar was demonstrated if the lower limit of CI for the treatment difference was greater than zero.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6.3</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.1</ci_lower_limit>
            <ci_upper_limit>14.7</ci_upper_limit>
            <estimate_desc>MMRM was used for analyses with covariates (treatment, region, baseline BCVA, CRT, choroidal neovascularization lesion type, visit, visit by baseline BCVA and treatment by visit interaction) with unstructured covariance matrix.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Gain of 15 or More ETDRS Letters in BCVA From Baseline in Study Eye at Week 52</title>
        <description>BCVA was measured using an eye chart and reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>ITT population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg (rQ4)</title>
            <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Gain of 15 or More ETDRS Letters in BCVA From Baseline in Study Eye at Week 52</title>
          <description>BCVA was measured using an eye chart and reported as the number of letters read correctly using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. The study eye is defined as the eye that meets the entry criteria. If both eyes met the entry criteria, the eye with the worse BCVA at baseline (Day 1) was selected as the study eye. If both eyes had same BCVA values at baseline (Day 1), then the participant had to select their non-dominant eye for treatment, or else the right eye was selected as the study eye.</description>
          <population>ITT population included all randomized participants.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
                <count group_id="O2" value="313"/>
                <count group_id="O3" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6"/>
                    <measurement group_id="O2" value="19.2"/>
                    <measurement group_id="O3" value="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-4.7</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.5</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <estimate_desc>The 95.1% CI for the weighted difference were calculated based on the Newcombe method using the Cochran-Mantel-Haenszel weights and baseline BCVA (≤55 vs &gt;55 letters) as the stratification factor.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>-8.2</param_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.7</ci_lower_limit>
            <ci_upper_limit>-1.5</ci_upper_limit>
            <estimate_desc>The 95.1% CI for the weighted difference were calculated based on the Newcombe method using the Cochran-Mantel-Haenszel weights and baseline BCVA (≤55 vs &gt;55 letters) as the stratification factor.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score in Study Eye at Week 52</title>
        <description>NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision related function. The overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding the general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye was defined as eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (day 1) was selected. If BCVA values for both eyes were identical then participant had to select non-dominant eye, or else right eye was selected as study eye. A positive change from baseline indicates improvement. MMRM analysis was used.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>ITT population included all randomized participants. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>Abicipar Pegol 2 mg (2Q8)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O2">
            <title>Abicipar Pegol 2 mg (2Q12)</title>
            <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab 0.5 mg (rQ4)</title>
            <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score in Study Eye at Week 52</title>
          <description>NEI-VFQ-25 consists of 25 vision-targeted questions that represent 11 vision-related quality of life subscales and one general health item. Responses of individual participants were recorded as scores that ranged between 0 (worst) to 100 (best vision related function) with higher scale indicating better vision related function. The overall composite score is then calculated by averaging over all 11 vision-targeted subscale scores, excluding the general health score. Overall composite score was calculated based on mean of non-missing subscales. Study eye was defined as eye that meets entry criteria. If both eyes met all of entry criteria, eye with worse BCVA at baseline (day 1) was selected. If BCVA values for both eyes were identical then participant had to select non-dominant eye, or else right eye was selected as study eye. A positive change from baseline indicates improvement. MMRM analysis was used.</description>
          <population>ITT population included all randomized participants. Number of participants analyzed was based on observed data; missing data were not imputed.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="273"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="0.7"/>
                    <measurement group_id="O2" value="3.7" spread="0.7"/>
                    <measurement group_id="O3" value="4.6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of abicipar was demonstrated if the lower limit of CI for the treatment difference was greater than zero.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>-0.0</ci_upper_limit>
            <estimate_desc>MMRM was used for analyses with covariates (treatment, region, baseline BCVA, visual function questionnaire (VFQ) score, visit, visit by baseline BCVA and treatment by visit interaction) with unstructured covariance matrix.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of abicipar was demonstrated if the lower limit of CI for the treatment difference was greater than zero.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95.1</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.7</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>MMRM was used for analyses with covariates (treatment, region, baseline BCVA, visual function questionnaire (VFQ) score, visit, visit by baseline BCVA and treatment by visit interaction) with unstructured covariance matrix.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to last dose of study drug (Up to Week 104)</time_frame>
      <desc>Safety population included all treated participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Abicipar Pegol 2 mg (2Q8)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 8 and every 8 weeks (2Q8) thereafter through Week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="E2">
          <title>Abicipar Pegol 2 mg (2Q12)</title>
          <description>Abicipar pegol 2 mg was administered to the study eye by intravitreal injection on Day 1, Week 4, Week 12, and every 12 weeks (2Q12) thereafter through week 96. Scheduled visits occurred every 4 weeks. To maintain masking, sham was administered to the study eye at scheduled visits where abicipar was not administered.</description>
        </group>
        <group group_id="E3">
          <title>Ranibizumab 0.5 mg (rQ4)</title>
          <description>Ranibizumab (Lucentis®) 0.5 mg was administered to the study eye by intravitreal injection every 4 weeks (rQ4) from Day 1 through Week 96.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinal pigment epithelial tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinal vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Vitritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Autoimmune uveitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Macular scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Optic disc haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Vitreous adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Necrotising retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Subretinal fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Femoral hernia incarcerated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Barrett’s oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cataract operation complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Inflammation of wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Ocular procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Procedural vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Adult failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Dupuytren’s contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Ankle deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bone sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bowen’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Head and neck cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Spinal cord neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Quadrantanopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Intensive care unit delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="202" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="196" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Subretinal fluid</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="310"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="312"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="310"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>IR-CTRegistration@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

